<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321214</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR6004</org_study_id>
    <nct_id>NCT03321214</nct_id>
  </id_info>
  <brief_title>Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease</brief_title>
  <official_title>A Pilot Study to Test the Feasibility and Acceptability of Using a Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current treatment for celiac disease is a strict 100% gluten free diet. Little is known
      about the best way to promote adherence to such a strict diet and how to maximize quality of
      life at the same time.

      This pilot will look at the utility of a new innovation to promote gluten free diet adherence
      - a portable gluten sensor device. Participants will be 30 teenagers and adults with celiac
      disease recruited from the Celiac Disease Center at Columbia University in New York City.
      Before and after the intervention, participants will be asked about their adherence to a
      gluten free diet, quality of life, symptoms, and feelings of anxiety, and depression. This
      pilot data will help to inform interventions that the investigators hope to test in a larger
      NIH-funded trial to better understand the best ways to promote adherence and quality of life
      in celiac patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little is known about the best ways to promote a strict gluten-free diet while maximizing
      quality of life in teenagers and adults with celiac disease. The aim of the proposed pilot is
      to assess the acceptability and feasibility of a novel intervention - a portable gluten
      sensor device. The sample for this pilot will be 30 teenagers and adults with biopsy
      confirmed celiac disease recruited from the Celiac Center at Columbia University in New York
      City. Thirty participants will pilot test a portable gluten sensor device with its associated
      iPhone app for 3 months. At baseline and three-month follow-up, participants will complete
      measures of gluten free diet adherence, quality of life,symptoms, anxiety, and depression. At
      post-only, the investigators will collect in-depth data related to the feasibility and
      acceptability of the gluten sensor, as well as facilitators and barriers related to how,
      where, and when it was used. At the completion of the proposed pilot study, the investigators
      hope to have preliminary data to inform development of gluten sensor interventions that the
      investigators hope to test in a larger NIH-funded randomized controlled trial. These
      findings, in combination with a larger trial, have the potential for the development of a new
      standard of care in the management of patients with celiac disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life measure</measure>
    <time_frame>3 months</time_frame>
    <description>A 20-item Celiac Disease-Quality of Life (CD-QOL) survey or 17-item Celiac Disease Pediatric Quality of (CDPQOL) survey. Each of these scales ranges from a minimum of 0 (lowest quality of life) to 100 (highest quality of life).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>3 months</time_frame>
    <description>The 21 item Beck Depression Inventory (BDI). This depression scale ranges from 0 (fewer symptoms) to 60 (most symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the gluten-free diet</measure>
    <time_frame>3 months</time_frame>
    <description>A 7-item validated CD adherence test (CDAT) survey. Higher scores suggest worse adherence (with scores &gt;13 indicative of poor adherence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Celiac disease symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Celiac Disease Symptom Diary (CDSD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>3 months</time_frame>
    <description>21 item Beck Anxiety Inventory. This anxiety index ranges from 20 (lower anxiety) to 100 (greater anxiety).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Light use of Nima</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate use of Nima</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heavy use of Nima</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gluten Sensor Device</intervention_name>
    <description>Gluten Sensor Device Dose-Finding Intervention Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes.
Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a &quot;smiley face&quot; if the food or beverage is &lt; 20 ppm or a wheat icon for &gt; 20 ppm (low or high gluten).
Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. Ten participants will be randomized to receive 24 capsules per month; ten participants will be randomized to receive 12 capsules per month; and ten participants will be randomized to receive 12 capsules every other month. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants.</description>
    <arm_group_label>Light use of Nima</arm_group_label>
    <arm_group_label>Moderate use of Nima</arm_group_label>
    <arm_group_label>Heavy use of Nima</arm_group_label>
    <other_name>Nima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals &gt;13 years old (15 teenagers and 15 adults), 30 in total with duodenal
             biopsy-confirmed diagnosis of celiac disease will be recruited to participate.

          -  As we are testing a gluten sensor device, we require that participants are 13 years or
             older as they will need to be able to operate the gluten sensor device independently

        Exclusion Criteria:

          -  No participants will be excluded based on gender, race or ethnicity.

          -  Patients diagnosed with celiac disease without a duodenal biopsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Lebwohl, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Lebwohl, MD,MS</last_name>
    <phone>(212)305-5590</phone>
    <email>bl114@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randi Wolf, Ph.D., MPH</last_name>
    <phone>(212) 678-3912</phone>
    <email>rlw118@tc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Celiac Disease Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Lebwohl, MD,MS</last_name>
      <phone>212-305-5590</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Lebwohl, MD,MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randi Wolf, Ph.D.,MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://nimasensor.com.</url>
    <description>Gluten sensor device website</description>
  </link>
  <reference>
    <citation>Green PH, Krishnareddy S, Lebwohl B. Clinical manifestations of celiac disease. Dig Dis. 2015;33(2):137-40. doi: 10.1159/000370204. Epub 2015 Apr 22. Review.</citation>
    <PMID>25925914</PMID>
  </reference>
  <reference>
    <citation>Abu Daya H, Lebwohl B, Lewis SK, Green PH. Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1472-7. doi: 10.1016/j.cgh.2013.05.030. Epub 2013 Jun 10.</citation>
    <PMID>23756221</PMID>
  </reference>
  <reference>
    <citation>Rubio-Tapia A, Kyle RA, Kaplan EL, Johnson DR, Page W, Erdtmann F, Brantner TL, Kim WR, Phelps TK, Lahr BD, Zinsmeister AR, Melton LJ 3rd, Murray JA. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology. 2009 Jul;137(1):88-93. doi: 10.1053/j.gastro.2009.03.059. Epub 2009 Apr 10.</citation>
    <PMID>19362553</PMID>
  </reference>
  <reference>
    <citation>Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012 Oct;107(10):1538-44; quiz 1537, 1545. doi: 10.1038/ajg.2012.219. Epub 2012 Jul 31.</citation>
    <PMID>22850429</PMID>
  </reference>
  <reference>
    <citation>Lohi S, Mustalahti K, Kaukinen K, Laurila K, Collin P, Rissanen H, Lohi O, Bravi E, Gasparin M, Reunanen A, Mäki M. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007 Nov 1;26(9):1217-25.</citation>
    <PMID>17944736</PMID>
  </reference>
  <reference>
    <citation>Meyer D, Stavropolous S, Diamond B, Shane E, Green PH. Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol. 2001 Jan;96(1):112-9.</citation>
    <PMID>11197239</PMID>
  </reference>
  <reference>
    <citation>Lebwohl B, Granath F, Ekbom A, Smedby KE, Murray JA, Neugut AI, Green PH, Ludvigsson JF. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med. 2013 Aug 6;159(3):169-75. doi: 10.7326/0003-4819-159-3-201308060-00006.</citation>
    <PMID>23922062</PMID>
  </reference>
  <reference>
    <citation>Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther. 2009 Aug 15;30(4):315-30. doi: 10.1111/j.1365-2036.2009.04053.x. Epub 2009 May 26. Review.</citation>
    <PMID>19485977</PMID>
  </reference>
  <reference>
    <citation>Comino I, Fernández-Bañares F, Esteve M, Ortigosa L, Castillejo G, Fambuena B, Ribes-Koninckx C, Sierra C, Rodríguez-Herrera A, Salazar JC, Caunedo Á, Marugán-Miguelsanz JM, Garrote JA, Vivas S, Lo Iacono O, Nuñez A, Vaquero L, Vegas AM, Crespo L, Fernández-Salazar L, Arranz E, Jiménez-García VA, Antonio Montes-Cano M, Espín B, Galera A, Valverde J, Girón FJ, Bolonio M, Millán A, Cerezo FM, Guajardo C, Alberto JR, Rosinach M, Segura V, León F, Marinich J, Muñoz-Suano A, Romero-Gómez M, Cebolla Á, Sousa C. Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. Am J Gastroenterol. 2016 Oct;111(10):1456-1465. doi: 10.1038/ajg.2016.439. Epub 2016 Sep 20. Erratum in: Am J Gastroenterol. 2017 Jul;112(7):1208.</citation>
    <PMID>27644734</PMID>
  </reference>
  <reference>
    <citation>Silvester JA, Graff LA, Rigaux L, Walker JR, Duerksen DR. Symptomatic suspected gluten exposure is common among patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther. 2016 Sep;44(6):612-9. doi: 10.1111/apt.13725. Epub 2016 Jul 22.</citation>
    <PMID>27443825</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Benjamin Lebwohl</investigator_full_name>
    <investigator_title>Herbert Irving Assistant Professor of Medicine and Assistant Professor of Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Gluten Free diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

